Abbott launched SimpleScreen CRC. Abbott Laboratories stock gained 1.40 percent.
Published on 10/09/2026 at 16:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Abbott launched the SimpleScreen CRC blood test for average-risk adults on September 30, 2026.
- SimpleScreen CRC reported 81.10 percent overall sensitivity and 90.40 percent specificity in a cited analysis.
- Abbott stock was at EUR 89.27 at Lang & Schwarz on October 9, 2026, up 1.40 percent.
- Third-quarter results are scheduled for October 21, 2026, with an ex-dividend date of October 15, 2026.
Abbott Laboratories (ISIN US0028241000) was trading at EUR 89.27 at Lang & Schwarz on October 9, 2026 at 4:34 p.m. CEST, up 1.40 percent. On September 30, 2026, Abbott launched SimpleScreen CRC, an FDA-approved blood test that adds a blood-based option for colorectal cancer screening.
SimpleScreen expands screening options
According to PR Newswire, Abbott commercialized SimpleScreen CRC in the United States for average-risk adults aged 45 and older. Medicare Part B covers the test for eligible patients without out-of-pocket costs.
The launch broadens Abbott's diagnostics portfolio alongside Cologuard Plus. Fierce Biotech reported 81.10 percent overall sensitivity, 63.50 percent sensitivity for stage I colorectal cancer and 90.40 percent specificity in a prespecified analysis.
Three dated Abbott events
On July 16, 2026, Abbott reported second-quarter sales of USD 12.593 billion, up 13.00 percent year over year, with adjusted diluted earnings per share of USD 1.31, according to TickerScout. On September 14, 2026, Abbott agreed to a USD 385 million settlement related to infant-formula claims, as reported by The Wall Street Journal. On September 30, 2026, the SimpleScreen CRC launch became Abbott's latest dated operating development, per PR Newswire.
What does the launch add?
The commercial value is access: a blood draw can reach adults who decline or do not complete stool-based screening. The 81.10 percent overall sensitivity and 90.40 percent specificity give the launch measurable clinical context, while a positive result still requires follow-up colonoscopy.
Upcoming dates for Abbott
MarketBeat lists October 15, 2026 as Abbott's ex-dividend date for its USD 0.63 quarterly dividend. The company is scheduled to report third-quarter 2026 results before the market opens on October 21, 2026, giving investors the next test of its USD 5.45 to USD 5.60 full-year adjusted earnings-per-share guidance.
Stock trades higher in afternoon trading
Abbott Laboratories was trading at EUR 89.27 at Lang & Schwarz on October 9, 2026 at 4:34 p.m. CEST, plus 1.40 percent versus the prior close of EUR 88.04 on October 8, 2026. The stock's market capitalization was USD 173.0 billion, while its 52-week range was USD 81.97 to USD 134.50 as of October 9, 2026.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories stock facts
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 9, 2026, 4:34 p.m. CEST): EUR 89.27
- Change versus prior close: plus 1.40 percent
- Prior close Lang & Schwarz (October 8, 2026): EUR 88.04
- Market capitalization: USD 173.0 billion (as of October 9, 2026)
- 52-week range: USD 81.97-134.50 (as of October 9, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Next earnings date: October 21, 2026
Market context: Market report S&P 500.
